CTI BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	156.38	141.59	84.09	38.98	38.74
Revenue Growth (YoY)	18.88%	68.39%	115.69%	0.62%	-
Cost of Revenue	130.11	128.34	73.79	34.81	32.64
Gross Profit	26.27	13.25	10.29	4.18	6.1
Selling, General & Admin	65.79	51.64	63.37	12.54	14.86
Operating Expenses	65.79	51.64	63.37	12.54	14.86
Operating Income	-39.52	-38.39	-53.08	-8.36	-8.76
Interest Expense	-14.26	-7.42	-5.37	-5.68	-5.38
Other Non Operating Income (Expenses)	0.14	0.14	0.31	-	-0.05
EBT Excluding Unusual Items	-53.64	-45.67	-58.13	-14.04	-14.19
Merger & Restructuring Charges	-	-	-0.03	-	-
Asset Writedown	-	-	-	-1.5	-
Other Unusual Items	0.35	-	-8.93	-	-
Pretax Income	-53.29	-45.67	-67.09	-15.54	-14.19
Income Tax Expense	-	-	-	0.02	-
Earnings From Continuing Operations	-53.29	-45.67	-67.09	-15.56	-14.19
Minority Interest in Earnings	38.11	34.68	32.12	-	-
Net Income	-15.18	-10.98	-34.98	-15.56	-14.19
Preferred Dividends & Other Adjustments	-	-	-24.83	0.55	0.42
Net Income to Common	-15.18	-10.98	-10.14	-16.11	-14.61
Shares Outstanding (Basic)	1	1	1	1	-
Shares Outstanding (Diluted)	1	1	1	1	-
Shares Change (YoY)	74.49%	0.38%	-29.08%	-	-
EPS (Basic)	-24.86	-21.28	-19.73	-22.22	-
EPS (Diluted)	-24.86	-21.28	-19.73	-22.22	-
Free Cash Flow	-38.36	-61.01	-29.29	-7.9	-11.41
Free Cash Flow Per Share	-62.81	-118.21	-56.97	-10.90	-
Gross Margin	16.80%	9.36%	12.24%	10.72%	15.75%
Operating Margin	-25.27%	-27.11%	-63.12%	-21.44%	-22.60%
Profit Margin	-9.71%	-7.76%	-12.06%	-41.32%	-37.70%
Free Cash Flow Margin	-24.53%	-43.09%	-34.83%	-20.27%	-29.46%
EBITDA	-33.31	-35.19	-51.94	-7.77	-8.24
EBITDA Margin	-21.30%	-24.85%	-61.77%	-19.93%	-21.27%
D&A For EBITDA	6.21	3.2	1.14	0.59	0.52
EBIT	-39.52	-38.39	-53.08	-8.36	-8.76
EBIT Margin	-25.27%	-27.11%	-63.12%	-21.44%	-22.60%

Updated Nov 14, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.